Pf-neostigmine Methylsulfate recalls
The FDA has published 2 recalls involving Pf-neostigmine Methylsulfate since 2022. The latest was reported on 23 Nov 2022. Most were for manufacturing (cgmp) deviations. Recalls usually affect specific lots, not every bottle on the market. Check the lot number on each recall page before acting.
Total recalls2since 2022
Last 12 months0reported
Class I00% of total
Ongoing0latest 23 Nov 2022
Recalls per month, last 24 months
click a bar for that monthSeverity split
Class I 0 0%Class II 2 100%Class III 0 0%
Why pf-neostigmine methylsulfate is recalled
Companies
By year
All pf-neostigmine methylsulfate recalls, newest first
2 total| Reported | Class | Recall | Company | Reason | Where |
|---|---|---|---|---|---|
| Drug | CLASS II | PF-Neostigmine Methylsulfate Injection, USP 3 mg/ (1 mg/mL) vial recalled | Nephron Sterile Compounding Center | Manufacturing (CGMP) Deviations | Nationwide |
| Drug | CLASS II | PF-Neostigmine Methylsulfate Injection, USP, 3 mg recalled | Nephron Sterile Compounding Center | Manufacturing (CGMP) Deviations | Nationwide |
Should you stop taking Pf-neostigmine Methylsulfate?
Not on your own. Most recalls affect specific lots from one manufacturer, and stopping a prescription suddenly can be riskier than the defect. Check your lot number and NDC against the recall, then call the pharmacy that dispensed it for a replacement.